Tissue samples prior to therapy were available for 9 out of 20 metastatic melanoma patients from cohort one. The samples were taken for diagnostic histological examination and were formalin-fixed and paraffin-embedded in the Department of Pathology of the Kantonsspital St. Gallen using the standard processing protocols. Four-micron-thick serial sections were then cut using a rotary microtome. Single epitope enzymatic immunohistochemistry on FFPE tissue was performed on serial sections to assess the % of tumor tissue expressing gp100 and MelanA/MART1 using a Leica BOND MAX automated immunostainer and the following antibodies: monoclonal mouse anti-human MelanA (Dako, catalog number
M7196, clone A103, dilution 1:150, HIER - pH 9/20 min/95 °C, incubation for 15 min), and monoclonal mouse anti-human Melanosome (Dako, catalog number
M0634, clone HMB-45, dilution 1:100, HIER - pH 6/20 min/100 °C, incubation for 30 min). Ten high power fields (HPF) equally distributed within the tumor were acquired from each case using a
Leica DM RA microscope equipped with a
Leica DFC420 C digital camera and processed using the
Leica Application Suite version 3.8.0 (Leica Microsystems, Switzerland). Quantitative morphometry was performed using the ImageJ public domain Java image processing program as described in the supporting methods [47 ].
Fässler M., Diem S., Mangana J., Hasan Ali O., Berner F., Bomze D., Ring S., Niederer R., del Carmen Gil Cruz C., Pérez Shibayama C.I., Krolik M., Siano M., Joerger M., Recher M., Risch L., Güsewell S., Risch M., Speiser D.E., Ludewig B., Levesque M.P., Dummer R, & Flatz L. (2019). Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Journal for Immunotherapy of Cancer, 7, 50.